曾庆平 教授,系主任 / Ching-Ping Tseng
职称： 教授／主任
现职： 长庚大学醫技系 系主任
电话： 5202
学歷： 美国威斯康辛麦迪逊分校人类肿瘤生物学博士
专长领域： 血小板生物学、转译癌症医学、分子检验技术学、血液学
个人网页：
研究方向及研究室特色(Lab & Research Interest)
本研究室主要探讨血小板活化的机制及血小板在癌症转移及血栓形成所扮演的角色；我们也开发癌症检测的平台，建立循环肿瘤细胞的检验方法并探讨循环肿瘤细胞的分子与细胞特性，将基础研究的成果转為临床检验的平台。以下為本研究室主要的研究方向:
探讨血小板活化的机制及血小板在癌症转移与血栓形成所扮演的角色
血小板自 100 年前首次在文献中被描述為「血液中的灰尘 (dust of the blood)」以来，一直被认為在止血及血栓形成的过程中扮演重要的角色。血小板的性质相当独特。它是最小的一种血球，但却是由骨髓中最大的巨核细胞 (megakaryocyte) 进行细胞质裂解而成。一个巨核细胞的细胞质先形成丝状的前驱血小板 (pro-platelet)，然后再裂解成 4000-5000 个血小板。近年的研究显示血小板功能的多样性，除了与心肌梗塞、缺血性中风、肺栓塞、骨髓增生性疾病(myeloproliferative disease)、及其他血栓或心血管疾病的发生有关外，也与癌症的转移、血液循环肿瘤细胞 (circulating tumor cells) 的存活、干细胞的分裂与分化、免疫、及微生物感染等皆息息相关。基於血小板的独特性质及与多种疾病的关联性，多年来我们与不同的研究团队合作，针对血小板在止血、血栓形成及癌症转移的机转上做深入的研究，藉此提供心血管疾病及癌症的预防与治疗上新的发展方向。主要的研究方向為:
(1) 探讨血小板蛋白 Disabled-2 (Dab2) 表现及磷酸化对血小板活化及血栓形成的影响。
(2) 探讨癌细胞表面蛋白 podoplanin (PDPN) 与 血小板蛋白 C–type lectin-like receptor 2 (CLEC-2) 交互作用在癌症转移上的生理病理功能。
(3) 以 PDPN-CLEC-2 交互作用為作用标的，开发抑制癌细胞转移的新医材。
深入瞭解:
(1) 曾庆平。血小板的奧妙与研究點滴。長庚校訊105年 第147期。
(2) Tsai HJ, Cheng JC, Kao ML, Chiu HP, Chiang YH, Chen DP, Rau KM, Liao HR, Tseng CP. Integrin αIIbβ3 outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2. Cell Biosci. 2021 Feb 8;11(1):32.
(3) Lee HY, Yu NY, Lee SH, Tsai HJ, Wu CC, Cheng JC, Chen DP, Wang YR, Tseng CP. Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer. Biomed J. 2020. Apr;43(2):146-162.
(4) Tseng CP , Huang YL, Chang YW, Liao HR, Chen YL, Hsieh PW. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2. J Food Drug Anal. Jan;28(1):115-123. 2020.
(5) Tsai HJ, Chien KY, Liao HR, Shih MS, Lin YC, Chang YW, Cheng JC, Tseng CP. Functional links between Disabled-2 Ser723 phosphorylation and thrombin signaling in human platelets. J Thromb Haemost. 2017 Oct;15(10):2029-2044.
(6) Tsai HJ, Tseng CP. The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling. Thromb J. 2016 Oct 4;14(Suppl 1):28.
(7) Tsai HJ, Huang CL, Chang YW, Huang DY, Lin CC, Cooper JA, Cheng JC, Tseng CP. Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice. Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2404-12.
(8) Chang YW, Hsieh PW, Chang YT, Lu MH, Huang TF, Chong KY, Liao HR, Cheng JC, Tseng CP. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget. 2015 Dec 15;6(40):42733-48.
循环肿瘤细胞检测平台之开发及其分子特性的探讨
癌症已连续多年位居国人十大死因之首位。癌细胞在身体内会藉由循环系统的携带，随着血液的流动而增加癌细胞远端转移到其他器官的机会。这些细胞称為循环肿瘤细胞 (circulating tumor cells, CTCs)。循环肿瘤细胞的數量及特性已經知道可以做為臨床藥物效率評估及癌症標靶藥物使用的參考。循环肿瘤细胞检测是採用液态活检 (liquid biopsy)，為一种非侵入式的血液檢測，近年已成為癌症檢測的一大趨勢。然而，循环肿瘤细胞檢測所面臨的最大挑戰是從五十億到一百億個週邊血液細胞分離出極為罕見的循环肿瘤细胞。
我们研究室建立了一个负向筛选 (negative selection) 的檢測平台以分離与純化循环肿瘤细胞，提供轉譯癌症醫學在臨床應用与基礎研究一個簡便的循环肿瘤细胞偵測系統。此技術平台可有效降低紅血球与白血球殘留率，提高分離出腫瘤細胞的純度。所分離出來之有核細胞可進行全基因定序、特定基因突變偵測等檢測，有利於醫師判斷用藥方向。該技術平台並獲得科技部创新创业激励计画创业潜力奖。除了臨床應用平台的建立外，我們的研究也著重在探討循环肿瘤细胞的分子与細胞特性，以瞭解癌症轉移的病理基礎。
深入瞭解:
(1) Tsai WS, Hung WS, Wang TM, Liu H, Yang CY, Wu SM, Hsu HL, Hsiao YC, Tsai HJ, Tseng CP. Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer. Biomed J.2021.
(2) Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential circulating tumor cell counts in patients with locally advanced or metastatic hepatocellular carcinoma: monitoring the treatment response. J Clin Med. Jan 10;9(1). pii: E188. 2020.
(3) Lin JD, Liou MJ, Hsu HL, Leong KK, Chen YT, Wang YR, Hung WS, Lee HY, Tsai HJ, Tseng CP. Circulating epithelial cell characterization and correlation with remission and survival in patients with thyroid cancer. Thyroid. 2018 Nov;28(11):1479-1489.
(4) Tseng CP, Leong KK, Liou MJ, Hsu HL, Lin HC, Chen YA, Lin JD. Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma. Oncotarget. 2017 Aug 24;8(44):77453-77464.
(5) Lin HC, Liou MJ, Hsu HL, Hsieh JC, Chen YA, Tseng CP, Lin JD. Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma. Oncotarget. 2016 Mar 29;7(13):17242-53.
(6) Hsieh JC, Lin HC, Huang CY, Hsu HL, Wu TM, Lee CL, Chen MC, Wang HM, Tseng CP. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head Neck. 2015 Oct;37(10):1448-55.
(7) Lin HC, Hsu HC, Hsieh CH, Wang HM, Huang CY, Wu MH, Tseng CP. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta. 2013 Apr 18;419:77-84.
论文与着作(笔耻产濒颈肠补迟颈辞苍)
代表性学术论文 (共 126 篇):
1. Chen DP, Tseng C-P (Co-first author), Wang WT, Sun CF. Genetic and mechanistic evaluation for the mixed-field agglutination in B3 blood type with IVS3+5G>A ABO gene mutation. PLoS One 7:e37272, 2012. (SCI)
2. Hung WS, Huang CL, Fan JT, Huang DY, Yeh CF, Cheng JC, Tseng C-P (Corresponding author). The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen. Biochim Biophys Acta. 1823:1778-1788, 2012. (SCI)
3. Lee TH, Wu TS, Tseng C-P (Co-corresponding author), Qiu JT. High-resolution melting molecular signatures for rapid identification of human papillomavirus genotypes. PLoS One, 7:e42051, 2012. (SCI)
4. Huang SB, Wu MH, Lin YH, Hsieh CH, Yang CL, Lin HC, Tseng C-P (Co-corresponding author), Lee GB. High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab Chip, 13:1371-83, 2013. (SCI)
5. Huang JT, Tseng C-P, Liao MH, Lu SC, Yeh WZ, Sakamoto N, Chen CM, Cheng JC. Hepatitis C virus replication is modulated by the interaction of non-structural protein NS5B and fatty acid synthase. J Virol. 87:4994-5004, 2013. (SCI)
6. Lin HC, Hsu HC, Hsieh CH, Wang HM, Huang CY, Wu MH, Tseng C-P (Corresponding author). A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta. 419C:77-84, 2013. (SCI)
7. Chang SS, Hsieh WH, Liu TS, Lee SH, Wang CH, Chou HC, Yeo YH, Tseng C-P (Co-corresponding author), Lee CC. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS One. 8:e62323, 2013. (SCI)
8. Chu HC, Lee HY, Huang YS, Tseng WL, Yen CJ, Cheng JC, Tseng C-P (Corresponding author). Erythroid differentiation is augmented in Reelin-deficient K562 cells and homozygous reeler mice. FEBS Lett. 588:58-64, 2014. (SCI)
9. Chen DP, Sun CF, Ning HC, Peng CT, Wang WT, Tseng C-P (Corresponding author). Real-time amplification of glyceraldehyde-3-phosphate dehydrogenase gene for quality control of leukopoor platelets. Transfusion. 54:445-50, 2014. (SCI)
10. Chu HC, Tseng WL, Lee HY, Cheng JC, Chang SS, Yung BY, Tseng C-P (Corresponding author). Distinct effects of Disabled-2 on transferrin uptake in different cell types and culture conditions. Cell Biol Int. 38:1252-1259, 2014. (SCI)
11. Tsai HJ, Huang CL, Chang YW, Huang DY, Lin CC, Cooper JA, Cheng JC, Tseng C-P (Corresponding author). Disabled-2 is required for efficient haemostasis and platelet activation by thrombin in mice. Arterioscler Thromb Vasc Biol 34:2404-2412, 2014. (SCI)
12. Tseng WL, Chen TH, Huang CC, Huang YH, Yeh CF, Tsai HJ, Lee HY, Kao CY, Lin SW, Liao HR, Cheng JC, Tseng C-P (Corresponding author). Impaired thrombin generation in Reelin-deficient mice: a potential role of plasma Reelin in hemostasis. J Thromb Haemost. 12:2054-2064, 2014. (SCI)
13. Chen DP, Sun CF, Ning HC, Peng CT, Wang WT, Tseng C-P (Corresponding author). Genetic and mechanistic evaluation for the weak A phenotype in Ael blood type with IVS6 + 5G>A ABO gene mutation. Vox Sang. 108:64-71, 2015. (SCI)
14. Hsieh CH, Lin HC, Huang CY, Hsu HL, Wu MH, Lee CL, Chen MC, Wang HM, Tseng C-P (Corresponding author). Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head Neck 37:1448-1455, 2015. (SCI)
15. Chang YW, Hsieh PW, Chang YT, Lu MH, Huang TF, Chong KY, Liao HR, Cheng JC, Tseng C-P (Corresponding author). Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget 6:42733-42748, 2015. (SCI)
16. Chen DP, Tseng C-P, Lin CJ, Wang WT, Sun CF. Mechanistic evaluation for mixed-field agglutination in the K562 cell study model with exon 3 deletion of A1 gene. Ann Clin Lab Sci. 45:674-679, 2015. (SCI)
17. Lin HC, Liou MJ, Hsu HL, Hsieh CH, Chen YA, Tseng C-P (Corresponding author), Lin JD. Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma. Oncotarget 7: 17242-17253, 2016. (SCI)
18. Hsieh CH, Lin HC, Huang SB, Hsueh C, Hsu HL, Wang HM, Wu MH, Tseng C-P (Corresponding author), Lin JD. Circulating epithelial cell enumeration facilitates the identification and follow-up of a patient with early stage papillary thyroid microcarcinoma: A case report. Clin Chim Acta. 454:107-111, 2016. (SCI)
19. Chen DP, Sun CF, Ning HC, Wang WT, Tseng C-P (Corresponding author). Comprehensive analysis of RHD splicing transcripts reveals the molecular basis for the weak anti-D reactivity of Del -red blood cells. Transfus Med. 26:123-129, 2016. (SCI)
20. Hung WS, Ling P, Cheng JC, Chang SS, Tseng C-P (Corresponding author). Disabled-2 is a negative immune regulator of lipopolysaccharide-stimulated Toll-like receptor 4 internalization and signaling. Sci Rep. 6:35343, 2016. (SCI)
21. Chen DP, Chang SW, Jaing TH, Tseng C-P, Chen SH, Wang WT. Effect of HLA mismatching at HLA-A, -B, and -DRB1 for umbilical-cord blood transplantation in Taiwan. Clin Chim Acta. 462:162-165, 2016. (SCI)
22. Tsai HJ, Tseng C-P (Corresponding author). The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling. Thromb J. 14(Suppl 1):28, 2016. Review
23. Cheng JC, Tseng C-P (Co-first author), Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Sci Rep. 7:4448, 2017. (SCI)
24. Tsai HJ, Chien KY, Liao HR, Shih MS, Lin YC, Chang YW, Cheng JC, Tseng C-P (Corresponding author). Functional links between Disabled-2 Ser723 phosphorylation and thrombin signaling in human platelets. J Thromb Haemost. 15:2029-2044, 2017. (SCI)
25. Chen DP, Wen YH, Lu JJ, Tseng C-P, Chen WL, Chang SW. Human platelet antigens are associated with febrile non-hemolytic transfusion reactions. Clin Chim Acta. 474:120-123, 2017. (SCI)
26. Tseng C-P (Corresponding author), Leong KK, Liou MJ, Hsu HL, Lin HC, Chen YA, Lin JD. Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma. Oncotarget. 8:77453-77464, 2017. (SCI)
27. Li YR, Tseng C-P (Co-first author), Hsu HL, Lin HC, Chen YA, Chen ST, Liou MJ, Lin JD. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody. Clin Chim Acta. 477:74-80, 2018. (SCI)
28. Chang YW, Tseng CP (Co-first autor), Lee CH, Hwang TL, Chen YL, Su MT, Chong KY, Lan YW, Wu CC, Chen KJ, Lu FH, Liao HR, Hsueh C, Hsieh PW. β-Nitrostyrene derivatives attenuate LPS-mediated acute lung injury via the inhibition of neutrophil-platelet interactions and NET release. Am J Physiol Lung Cell Mol Physiol. 314:L654-L669, 2018. (SCI)
29. Chen DP, Wen YH, Lu JJ, Tseng C-P, Wang WT. Rapid rare ABO blood typing using a single PCR based on a multiplex SNaPshot reaction. J Formos Med Assoc. 2018. (SCI)
30. Chen DP, Chang SW, Jaing TH, Wang WT, Hus FP, Tseng C-P (Corresponding author). Single nucleotide polymorphisms within HLA region are associated with disease relapse for patients with unrelated cord blood transplantation. Peer J. 6:e5228, 2018. (SCI)
31. Lin JD, Liou MJ, Hsu HL, Leong KK, Chen YT, Wang YR, Hung WS, Lee HY, Tsai HJ, Tseng C-P (Corresponding author). Circulating epithelial cell characterization and correlation with remission and survival in patients with thyroid cancer. Thyroid. 28:1479-1489, 2018. (SCI)
32. Chen DP, Chang SW, Wang PN, Hus FP, Tseng C-P (Corresponding author). Association between single nucleotide polymorphisms within HLA region and disease relapse for patients with hematopoietic stem cell transplantation. Sci Rep. Sep 24;9(1):13731. 2019. (SCI)
33. Watanabe N, Kidokoro M, Suzuki Y, Tanaka M, Inoue S, Tsukamoto H, Hirayama N, Hsieh PW, Tseng CP, Nakagawa Y, Inokuchi S. A pull-down and slot blot-based screening system for inhibitor compounds of the podoplanin-CLEC-2 interaction. PLoS One. Sep 25;14(9):e0222331. 2019. (SCI)
34. Tseng C-P (Co-first author), Huang YL, Chang YW, Liao HR, Chen YL, Hsieh PW. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2. J Food Drug Anal. Jan;28(1):115-123. 2020. (SCI)
35. Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng C-P (Corresponding author). Sequential circulating tumor cell counts in patients with locally advanced or metastatic hepatocellular carcinoma: monitoring the treatment response. J Clin Med. Jan 10;9(1). pii: E188. 2020. (SCI)
36. Lee HY, Yu NY, Lee SH, Tsai HJ, Wu CC, Cheng JC, Chen DP, Wang YR, Tseng C-P (Corresponding author). Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer. Biomed J. Apr;43(2):146-162. 2020. (SCI)
37. Tsai HJ, Cheng JC, Kao ML, Chiu HP, Chiang YH, Chen DP, Rau KM, Liao HR, Tseng C-P (Corresponding author). Integrin αIIbβ3 outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2. Cell Biosci. Feb 8;11(1):32. 2021. (SCI)
38. Tsai WS, Hung WS, Wang TM, Liu H, Yang CY, Wu SM, Hsu HL, Hsiao YC, Tsai HJ, Tseng C-P (Corresponding author). Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer. Biomed J.2021. (SCI)
专利:
1. 曾庆平、谢珮文、张耀文。一种含有5-硝基苯之衍生物，透過抑制腫瘤細胞誘發血小板凝集反應作為癌症轉移治療方式。中華民國专利 I444358。
2. 曾庆平、谢珮文、张耀文。Composition of 5-nitrobenzoate derivatives as anti-metastatic agent that inhibits tumor cell-induced platelet aggregation. 美國专利9956191。
3. 曾庆平、谢珮文、张耀文。Composition of 5-nitrobenzoate derivatives as anti-metastatic agent that inhibits tumor cell-induced platelet aggregation. 美國专利9604910。
4. 谢珮文、曾庆平、蔡昀真, 黄鈺凌、张耀文。Compounds, compositions and methods for treating tumors. 美國专利 10047039。
5. 张国友、曾庆平。氯硝柳氨及其衍生物的用途. 中華民國专利申請案I631944。
6. 张国友、曾庆平。Method of using niclosamide derivatives。美國专利申請案15/481455。
7. 曾庆平、张诗鑫。擴增与檢測目標微生物DNA的方法、組成与系統。中華民國专利I465572。
8. 曾庆平、张诗鑫。Methods, systems, and compositions for detection of microbial DNA by PCR. 美國专利 9388458。
9. 曾庆平、张诗鑫。Methods, systems, and compositions for detection of microbial DNA by PCR. 澳洲专利 AU-B-2012255042。
10. 曾庆平、张诗鑫。Methods, systems, and compositions for detection of microbial DNA by PCR. 蘇俄专利2620953。
11. 马蕴华、曾庆平、郑凯文(2019) 用以标的凝血因子XIII的適體及其用途。中華民國专利公開號202122581。
12. 马蕴华、曾庆平、郑凯文(2019) 用以標的第十三凝血因子之核苷酸適體及其用途。美國专利申請。
专书:
1. 医学分子检验 (五南出版社)，2013 (初版) – 2018 (五版)。
第一章?分子检验基本技术（吴芳姿、王圣帆、许蕙玲、杨正芬、黄智生、郑如茜、黄家群、曾庆平、孙光蕙?着）
第四章 高通量定序技术於分子检验之应用（邱全芊、骆纪东、黄家群、曾庆平着）
第二十五章?癌症标靶药物疗效评估之分子检测（曾庆平、邱全芊、黄家群、陈泰龙 着）
获奖情形:
教师 (详见研究室网页):
1. 长庚大学优良教师教學奖, 2017.
2. 长庚大学优良教师研究奖, 2016.
3. 科技部创新创业激励计画创业潜力奖, 2014.
4. 台湾医检学会学术论文奖, 2011.
5. 长庚大学优良教师研究奖, 2008.
6. 台湾医检学会 Sysmex 论文奖, 2006.
7. 国际血栓暨止血学会 Reach The World 奖, 2005.
8. 台湾医检学会学术论文奖, 2003.
9. 國科會研究類甲種奖, 2001.
10. 长庚大学优良教师輔導奖, 2000.
11. 台湾医事检验学会108年度臨床應用組學術论文奖,2019
12. 开发之技术「IronMag循环肿瘤细胞自動化檢測系統」(已技转至荣文生医)，获颁「第17屆國家新創奖」企業新創組的生技製藥与精準醫療類奖項, 2021.
研究室成员 (详见研究室网页):
1. Huang CL (黄千凌). 徐千田優秀论文奖, The 14th Symposium on recent advances in cellular and molecular biology. Taiwan 2006.
2. Huang CL (黄千凌). 最佳壁報奖, The 21st Joint Annual Conference of Biomedical Sciences-2006.
3. Huang CL (黄千凌). 年輕學者研究奖, The International Society on Thrombosis & Haemostatsis XXIIIrd Congress, Kyoto, Japan, 2011.
4. Tseng WL (曾维廉). JSTH 亞太奖學金, The International Society on Thrombosis & Haemostatsis XXIIIrd Congress, Kyoto, Japan, 2011.
5. Lin HC (林鸿至). 最佳壁報奖. CellTech 2013 - Circulating tumor cells, 2013.
6. Tsai HJ (蔡蕙如). Reach the World Awards, The International Society on Thrombosis & Hemostatsis XXIV Congress, Amsterdam, Netherlands, 2013.
7. Tseng WL (曾维廉). Reach the World Awards, The International Society on Thrombosis & Haemostasis XXIV Congress, Amsterdam, Netherlands, 2013.
8. Tseng WL (曾维廉). 年輕學者研究奖, The International Society on Thrombosis & Hemostasis XXIV Congress, Amsterdam, Netherlands, 2013.
9. Hung WS (洪伟珊). AAI 最佳摘要奖, Annual Meeting for the American Association of Immunology, 2015.
10. Chang YW (张耀文). Reach the World Awards, The International Society of Thrombosis and Hemostasis Congress, 2015.
11. Tsai HJ (蔡蕙如). 年輕學者研究奖, The JSTH/APSTH Joint Symposium, 2016.
12. Tsai HJ (蔡蕙如). 年輕學者研究奖, The 9th Congress of the Asia-Pacific Society on Thrombosis and Hemostasis, 2016.
13. Lee SY (李星莹). 最佳壁報奖. The 9th Congress of the Asia-Pacific Society on Thrombosis and Hemostasis, 2016.
14. Tsai HJ (蔡蕙如). Reach the World Awards, The International Society of Thrombosis and Hemostasis Congress, 2017.
15. Tsai HJ (蔡蕙如). 最佳壁報奖, The 10th Congress of the Asia-Pacific Society on Thrombosis and Hemostasis, 2018.
16. 陳鈺婷、李星莹. e-Poster優秀论文奖, 台湾医事检验学会年會, 2019.
17. 黄冠达. 学生论坛第二名, 台湾医事检验学会年會, 2019.
18. 吴世政. 醫技系第十八屆硕士论文竞赛?優選, 2021.
科技部大专生计画
1. 林彦嘉. 研究题目：探讨Disabled-2磷酸化与蛋白質交互作用的影響 (104学年度)
2. 郑雁如. 研究题目：PowerMag循环肿瘤细胞分離平台純化能力提升之探討 (105学年度)
3. 李亚芸. 研究题目：Disabled-2的表现及其S723位点的磷酸化在口腔癌细胞所扮演的角色(105学年度)
4. 李婉琳. 研究题目：建立anti-Dab2 Ser394磷酸化之抗体并探讨Dab2 Ser394磷酸化在细胞週期的影响 (108学年度)
5. 黄薀宇. 研究题目：建立良好的血小板保存方式 (110学年度)
6. 李柔臻. 研究题目：Podoplanin適體的應用与功能性技術之開發 (110学年度)